Academic Journal
Effectiveness of tildrakizumab 200 mg: an Italian multicenter study
| العنوان: | Effectiveness of tildrakizumab 200 mg: an Italian multicenter study |
|---|---|
| المؤلفون: | Annunziata Dattola, Nicoletta Bernardini, Francesca Svara, Anna Balato, Giacomo Caldarola, Domenico D’Amico, Clara De Simone, Eugenia Veronica Di Brizzi, Maria Esposito, Claudia Giofrè, Domenico Giordano, Claudio Guarneri, Francesco Loconsole, Viviana Lora, Gaia Moretta, Diego Orsini, Severino Persechino, Concetta Potenza, Simone Ragonesi, Giovanni Pellacani, Ketty Peris, Maria Concetta Fargnoli, Antonio Giovanni Richetta |
| المصدر: | Journal of Dermatological Treatment, Vol 35, Iss 1 (2024) |
| بيانات النشر: | Taylor & Francis Group, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Dermatology |
| مصطلحات موضوعية: | Effectiveness, psoriasis, tildrakizumab, tildrakizumab 200 mg, anti-IL23, Dermatology, RL1-803 |
| الوصف: | Introduction: Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg dose may provide greater efficacy for patients over 90 kg or with high disease burden.Methods: This multicenter, prospective study evaluated the effectiveness and safety of tildrakizumab 200 mg in patients with moderate-to-severe psoriasis, focusing on those with specific challenges: body weight over 90 kg, baseline PASI ≥20, and difficult-to-treat areas. The study also compared bio-naive versus bio-experienced and male versus female patients. Adults received tildrakizumab 200 mg subcutaneously at weeks 0 and 4, then every 12 weeks.Results: Clinical improvements were assessed using PASI, DLQI, genital PASI, and NAPSI scores. After 24 weeks, the mean PASI score dropped from 14.6 to 0.4, with PASI 90 and PASI 100 scores exceeding 80% (100.0% and 80.3%, respectively). DLQI scores improved from 14.2 to 1.8, and significant improvements were seen in genital PASI and NAPSI scores. No significant adverse events occurred.Conclusions: Tildrakizumab 200 has been shown to be an effective therapeutic option, particularly for patients with high body weight, significant disease burden, and involvement of sensitive areas with no new safety signals. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 09546634 1471-1753 0954-6634 |
| Relation: | https://doaj.org/toc/0954-6634; https://doaj.org/toc/1471-1753 |
| DOI: | 10.1080/09546634.2024.2420825 |
| URL الوصول: | https://doaj.org/article/0025053498fe49b2841bd41e99bc2742 |
| رقم الانضمام: | edsdoj.0025053498fe49b2841bd41e99bc2742 |
| قاعدة البيانات: | Directory of Open Access Journals |
| تدمد: | 09546634 14711753 |
|---|---|
| DOI: | 10.1080/09546634.2024.2420825 |